Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Alessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20

Showing 20 citing articles:

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
Laura Pini, Diego Bagnasco, Bianca Beghè, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 3013-3013
Open Access | Times Cited: 9
Innate Immunity and Asthma Exacerbations: Insights From Human Models
Jehan Alladina, Benjamin D. Medoff, Christina Schofield
Immunological Reviews (2025) Vol. 330, Iss. 1
Closed Access | Times Cited: 1
OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial
Marianne Baastrup Soendergaard, Anne‐Sofie Bjerrum, Linda Rasmussen, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 2, pp. 2400404-2400404
Open Access | Times Cited: 5
Emerging biological treatments for asthma
Daniela Pastore, Chiara Lupia, Maria D’Amato, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries From Central Eastern Europe and Baltics
Florin Mihălţan, Zsuzsanna Csoma, Norbert Pauk, et al.
Journal of Asthma and Allergy (2025) Vol. Volume 18, pp. 195-210
Open Access
Serum and urine eosinophil-derived neurotoxin (EDN) levels predict biologic response in severe asthma
Yu Ri Kang, Hyun‐Kyoung Kim, Chae Eun Lee, et al.
World Allergy Organization Journal (2025) Vol. 18, Iss. 1, pp. 100990-100990
Closed Access
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study
Luisa Brussino, Maria Aliani, Elena Altieri, et al.
Frontiers in Allergy (2025) Vol. 6
Open Access
Eosinophilic Patterns in Patients with Seasonal Allergy Affected by Bronchial Asthma and Rhinitis/Rhinosinusitis: Efficacy of Benralizumab in Patients with the Persistent Pattern
Valentina D’Aiuto, Ilaria Mormile, Francescopaolo Granata, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 754-754
Open Access | Times Cited: 3
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
Laura Pini, Diego Bagnasco, Bianca Beghè, et al.
(2024)
Open Access | Times Cited: 3
SANI clinical remission definition: a useful tool in severe asthma management
Giorgio Walter Canonica, Diego Bagnasco, Benedetta Bondi, et al.
Journal of Asthma (2024) Vol. 61, Iss. 12, pp. 1593-1600
Open Access | Times Cited: 3
Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?
Corrado Pelaia, Antonio Giacalone, Gianluca Ippolito, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 45-51
Open Access | Times Cited: 2
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Paolo Cameli, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 273-290
Open Access | Times Cited: 2
The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma
Laura Bergantini, Tommaso Pianigiani, Miriana d’Alessandro, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115385-115385
Open Access | Times Cited: 5
Benralizumab: The Immuno-Pharmacological State of the Art
Alessandra Vultaggio, Marco Benci, Laura Bergantini, et al.
(2024)
Open Access | Times Cited: 1
Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab
David J. Jackson, Hassan Burhan, Hitasha Rupani, et al.
Clinical & Experimental Allergy (2024) Vol. 54, Iss. 10, pp. 734-746
Open Access | Times Cited: 1
The economic burden of asthma in Italy: evaluating the potential impact of different treatments in adult patients with severe eosinophilic asthma
Matteo Scortichini, Francesco Saverio Mennini, Andrea Marcellusi, et al.
The European Journal of Health Economics (2024)
Open Access | Times Cited: 1
Eosinophils and T2 inflammation in severe asthma
Agamemnon Bakakos, Nektarios Anagnostopoulos, Petros Bakakos
(2024) Vol. 2, Iss. 5, pp. 399-409
Open Access
Benralizumab: from tissue distribution to eosinophilic cytotoxicity up to potential immunoregulation
Alessandra Vultaggio, Laura Bergantini, Claudia Crimi, et al.
Expert Opinion on Biological Therapy (2024), pp. 1-11
Closed Access
Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma
Francesco Menzella, M. Marchi, Marco Caminati, et al.
Journal of Clinical Medicine (2024) Vol. 14, Iss. 1, pp. 191-191
Open Access
Pharmacologic Treatment of Type 2-High Severe Asthma
Annamaria Bosi, Maria Serena Simeone, Federica Ghinassi, et al.
Medical Research Archives (2024) Vol. 12, Iss. 4
Open Access
Page 1

Scroll to top